Summary
Medtronic plc reported net sales of $8.578 billion for the three months ended July 25, 2025, an 8% increase compared to the prior year period. This growth was driven by strong performance across most business segments, particularly Cardiovascular and Diabetes, with notable contributions from Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and the MiniMed 780G AID system. Net income attributable to Medtronic remained relatively flat at $1.040 billion ($0.81 diluted EPS) compared to $1.042 billion ($0.80 diluted EPS) in the prior year. The company's operational cash flow saw a healthy increase to $1.088 billion. Medtronic also highlighted progress in managing its cost structure and continued investment in research and development to drive future innovation, while navigating macroeconomic uncertainties such as tariffs.
Financial Highlights
53 data points| Revenue | $8.58B |
| Cost of Revenue | $3.00B |
| Gross Profit | $5.58B |
| SG&A Expenses | $2.81B |
| Operating Income | $1.45B |
| Net Income | $1.04B |
| EPS (Basic) | $0.81 |
| EPS (Diluted) | $0.81 |
| Shares Outstanding (Basic) | 1.28B |
| Shares Outstanding (Diluted) | 1.29B |
Key Highlights
- 1Net sales increased by 8% year-over-year to $8.578 billion, driven by broad-based growth across key segments.
- 2Diluted earnings per share remained stable at $0.81, reflecting consistent profitability on a per-share basis.
- 3Operating cash flow improved significantly to $1.088 billion, indicating strong operational cash generation.
- 4Cardiovascular and Diabetes segments showed robust growth, with net sales increasing by 9% and 12% respectively.
- 5The company is actively managing its balance sheet, with $1.273 billion in cash and cash equivalents and $6.848 billion in investments.
- 6Medtronic is proceeding with the planned separation of its Diabetes business, expected within 18 months.
- 7The company reported a slight increase in its effective tax rate to 19.6%, partly due to global minimum tax impacts.